UBS AM
MXCT icon

UBS AM’s MaxCyte MXCT Stock Holding History

UBS AM’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-203,648
Closed -$792K – 2726
2024
Q3 		$792K Sell
203,648
-27,111
-12% -$114K ﹤0.01% 2491
2024
Q2 		$905K Buy
230,759
+82,801
+56% +$356K ﹤0.01% 2428
2024
Q1 		$620K Hold
147,958
– – ﹤0.01% 2219
2023
Q4 		$695K Hold
147,958
– – ﹤0.01% 2209
2023
Q3 		$462K Buy
147,958
+85,745
+138% +$345K ﹤0.01% 2326
2023
Q2 		$308K Hold
62,213
– – ﹤0.01% 2471
2023
Q1 		$308K Sell
62,213
-687
-1% -$3.38K ﹤0.01% 2471
2022
Q4 		$343K Hold
62,900
– – ﹤0.01% 2304
2022
Q3 		$409K Hold
62,900
– – ﹤0.01% 2416
2022
Q2 		$298K Buy
62,900
+16,900
+37% +$83.2K ﹤0.01% 2481
2022
Q1 		$322K Hold
46,000
– – ﹤0.01% 2580
2021
Q4 		$469K Buy
+46,000
New +$494K ﹤0.01% 2586

Other funds holding MXCT

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM's MXCT Position: Q4 2024 in Review

UBS AM sold out of MaxCyte (MXCT) in Q4 2024, closing a stake of 203,648 shares — an estimated $792K sold.

UBS AM first reported a position in MXCT in Q4 2021 and held it in 12 quarters. The position peaked at $905K in Q2 2024. 119 funds tracked by Wall St. Rank hold MXCT as of Q4 2024.

  • UBS AM reported no remaining MaxCyte position as of Q4 2024 after selling out during the quarter.
  • UBS AM sold 203,648 MaxCyte shares in Q4 2024, an estimated $792K.
  • UBS AM first reported a position in MaxCyte in Q4 2021 and held it in 12 quarters.
  • UBS AM's MaxCyte position peaked at $905K in Q2 2024.
  • 119 funds tracked by Wall St. Rank held MaxCyte as of Q4 2024.

Based on UBS AM's 13F filing for Q4 2024, filed 14 Feb 2025.